For 2024, adjusted EPS from continuing operations was $8.29, up 4% from prior year. Revenue was $7.7 billion, an increase of 1%. Dover's CEO, Richard Tobin, said: "We are poised to deliver double ...
He expressed cautious optimism for double-digit EPS growth in 2025, adjusted for currency and tax effects, driven by cost-efficiency measures and ongoing operational improvements. Pharma’s Q4 ...